Skip to main content
Pharmicell Co.,Ltd. logo

Pharmicell Co.,Ltd. — Investor Relations & Filings

Ticker · 005690 ISIN · KR7005690003 KO Manufacturing
Open in API
Filings indexed 275 across all filing types
Latest filing 2018-12-14 Director's Dealing
Country KR South Korea
Listing KO 005690

About Pharmicell Co.,Ltd.

https://www.pharmicell.com/eng/

Pharmicell Co., Ltd. is a biopharmaceutical company specializing in stem cell technology and advanced bio-based materials. The company is a pioneer in regenerative medicine, having developed Hearticellgram-AMI, the world's first approved stem cell therapy for acute myocardial infarction. Its core business includes the development of stem cell therapeutics, a stem cell banking service for adult and cord blood cells, and a line of cosmetics based on stem cell culture media. A significant division focuses on fine chemicals, manufacturing and supplying critical raw materials for the pharmaceutical industry, such as nucleosides, mPEGs, and oligonucleotides for gene therapies. The company also produces eco-friendly flame retardants for industrial use.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details the change in share ownership for a specific individual (Kim Seong-lae) due to their resignation as a director. This type of filing is a standard disclosure for insider transactions or changes in holdings by company insiders, which corresponds to the 'Director's Dealing' category.
2018-12-14 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties (in this case, due to the resignation of an executive). This type of filing is classified as a Major Shareholding Notification (MRQ) as it tracks significant ownership thresholds and changes in control.
2018-12-14 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) filed by Pharmicell. It details changes in share ownership for specific individuals (major shareholders/executives) and provides a summary of total shareholding status. This type of filing is a standard regulatory disclosure regarding major shareholding notifications and changes in ownership stakes, which falls under the 'Major Shareholding Notification' category.
2018-12-14 Korean
단일판매ㆍ공급계약체결(자율공시)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from Pharmicell regarding a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약 체결) with Thermo Fisher Scientific. It details the contract amount, duration, and counterparty. Since this is a specific disclosure of a commercial contract and does not fit into categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2018-11-22 Korean
분기보고서 (2018.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Pharmicell Co., Ltd., covering the period from January 1, 2018, to September 30, 2018. It contains detailed corporate information, business descriptions, capital changes, and financial data structures typical of a formal quarterly filing submitted to the Financial Services Commission and the Korea Exchange. It is not an announcement or a certification, but the full report itself. 9M 2018
2018-11-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.